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Pseudogene transcripts can provide a novel tier
of gene regulation through generation of endoge-
nous siRNAs or miRNA-binding sites. Characteriza-
tion of pseudogene expression, however, has re-
mained confined to anecdotal observations due to
analytical challenges posed by the extremely close
sequence similarity with their counterpart coding
genes. Here, we describe a systematic analysis
of pseudogene ‘‘transcription’’ from an RNA-Seq
resource of 293 samples, representing 13 cancer
and normal tissue types, and observe a surprisingly
prevalent, genome-wide expression of pseudogenes
that could be categorized as ubiquitously expressed
or lineage and/or cancer specific. Further, we explore
disease subtype specificity and functions of selected
expressed pseudogenes. Taken together, we pro-
vide evidence that transcribed pseudogenes are
a significant contributor to the transcriptional land-
scape of cells and are positioned to play significant
roles in cellular differentiation and cancer progres-
sion, especially in light of the recently described
ceRNA networks. Our work provides a transcriptome
resource that enables high-throughput analyses of
pseudogene expression.INTRODUCTION
Pseudogenes are ancestral copies of protein-coding genes
that arise from genomic duplication or retrotransposition of
mRNA sequences into the genome followed by accumulation1622 Cell 149, 1622–1634, June 22, 2012 ª2012 Elsevier Inc.of deleterious mutations due to loss of selection pressure,
degenerating eventually into so-called genetic fossils (Sasid-
haran and Gerstein, 2008). Pseudogenes pervade the genome,
representing virtually every coding gene, and due to their
extremely close sequence similarity with their cognate genes,
complicate whole-genome sequencing and gene expression
analyses. A growing body of evidence strongly suggests their
potential roles in regulating cognate wild-type gene expres-
sion/function by serving as a source of endogenous siRNA
(Tam et al., 2008; Watanabe et al., 2008), antisense transcripts
(Zhou et al., 1992), competitive inhibitors of translation of
wild-type transcripts (Kandouz et al., 2004), and perhaps domi-
nant-negative peptides (Katoh and Katoh, 2003). Pseudogene
transcription has also been shown to regulate cognate wild-
type gene expression by sequestering miRNAs (Poliseno
et al., 2010). The recently described competing endogenous
RNA (ceRNA) networks comprising sets of coordinately ex-
pressed genes with shared miRNA response elements (MREs)
provide an additional dimension of (post-) transcriptional regu-
lation in which the role of pseudogenes might overlap with
those of protein-coding genes (Salmena et al., 2011; Sumazin
et al., 2011).
Previous genome-wide studies of pseudogenes focused on
the identification of their chromosomal coordinates and annota-
tions based on diverse computational approaches (Karro et al.,
2007; Zhang and Gerstein, 2004), including PseudoPipe (Zhang
et al., 2006), HAVANA (Solovyev et al., 2006), PseudoFinder (Lu
and Haussler, 2006, ASHG, conference), and Retrofinder (Zheng
and Gerstein, 2006). These individual pipelines were subse-
quently consolidated into an integrated consensus platform,
ENCyclopedia Of DNA Elements (ENCODE), which now serves
as the definitive database of manually curated and annotated
pseudogenes as well as pseudogene transcripts (Zheng et al.,
2007). By contrast, genome-wide analyses of pseudogene
expression have been somewhat arbitrary, mainly relying upon
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Figure 1. Pseudogene Expression Analysis
Pipeline
The bioinformatics pipeline for analyzing pseudo-
gene transcription involved the following steps: (1)
Paired-end transcriptome sequencing reads were
mapped to the human genome and UCSC Genes
using ELAND. (2) Passed purity (PF) filter reads
were assigned into three sequence bins as indi-
cated. (3) Paired reads with one or both partners
mapping to unannotated genomic regions were
clustered based on overlapping alignments. (4)
Clusters were filtered to remove singleton,
stacked, and duplicate reads. (5) To determine
a consensus pseudogene annotation, clusters
were scanned through the Yale and ENCODE
pseudogene databases as well as analyzed with
a BLAT-based custom homology search. Data
from individual samples were then compared to
generate pseudogene expression signatures.
Clusters not assigned at this stage were cat-
egorized as other potentially nonpseudogene
transcripts.
See also Figures S1, S2, and S3 and Tables S1
and S2.evidence of pseudogene transcripts obtained from disparate
gene expression platforms, including public mRNA and EST
databases, cap analysis gene expression (CAGE) studies, and
gene identification signature-paired end tags (GIS-PET) (Ruan
et al., 2007). Given the essentially anecdotal observations of
pseudogene expression, only 160 expressed human pseudo-
genes are currently documented in ENCODE. Though this could
be due to a general lack of transcription of pseudogenes, as
generally presumed, it may also be reflective of an insufficient
and uneven depth of coverage afforded by early gene expression
analysis tools.Cell 149, 1622–163In this context, the recent maturation
of next-generation high-throughput se-
quencing platforms provides unprece-
dented access to genome-wide expres-
sion analyses previously not achievable
(Han et al., 2011a; Morozova et al.,
2009). Here, we analyzed a compendium
of RNA-Seq transcriptome data specifi-
cally focusing on pseudogene transcripts
from a total of 293 samples encompass-
ing 13 different tissue types, including
248 cancer and 45 benign samples. In
order to carry out a systematic analysis
of pseudogene expression, we devel-
oped a bioinformatics pipeline focused
on detecting pseudogene transcription.
This integrative approach provided
evidence of expression for 2,082 distinct
pseudogenes, which displayed lineage-
specific, cancer-specific, as well as
ubiquitous expression patterns. Taken
together, this Resource nominates a
multitude of expressed pseudogenesthat merit further investigation to determine their roles in biology
and in human disease.
RESULTS
Development of a Bioinformatics Platform
for the Analysis of Pseudogene Transcription
Paired-end RNA-Seq data from a compendium of 293 samples,
representing both cancer and benign samples from 13 different
tissue types recently generated in our laboratory, was utilized
to build a pseudogene analysis pipeline (Figure 1 and Figure S14, June 22, 2012 ª2012 Elsevier Inc. 1623
and Table S1 available online). Sequencing reads were mapped
to the human genome (hg18) and University of California Santa
Cruz (UCSC) Genes using Efficient Alignment of Nucleotide
Databases (ELAND) software of the Illumina Genome Analyzer
Pipeline (Table S2). Reads showing mismatches to the reference
genes but mapping perfectly to unannotated regions elsewhere
in the genome were used as the primary data for pseudogene
expression analysis. Two or more unique, high-quality overlap-
ping reads nucleating at the loci of differences between wild-
type genes and pseudogenes were used to define de novo
‘‘clusters’’ (ranging from 40 to 5,000 bp). These clusters were
employed for gene expression analyses in a way analogous to
the ‘‘probes’’ used in microarray gene expression studies,
though unlike predesigned and fixed probes used in microar-
rays, the sequence clusters used here were formed de novo,
solely based on the presence (and levels) of transcripts. Thus,
one or more clusters (like one or more probes in microarrays)
represented a transcript, whereas the number of reads mapping
to a cluster (analogous to fluorescence intensity due to probe
hybridization on microarrays) provided a measure of expression
of the corresponding (pseudo)genes. For example, Figure 2
shows a schematic representation of the cluster alignments for
two representative pseudogenes, ATP8A2-J (Figure 2A) and
CXADR-J (Figure 2B). As can be seen, mutation-dense regions
in the reference sequence provide foci of pseudogene-specific
cluster formation. Naturally, pseudogenes with sparse and
dispersed mutations nucleate fewer clusters and require higher
depth of coverage for reliable detection.
Overall, 2,156 unique pseudogene transcript clusters were
identified, and their genomic coordinates (start and end points)
were compared with the coordinates of pseudogenes annotated
in the ENCODE (Zheng et al., 2007) and Yale pseudogene
resources (http://www.pseudogene.org) (Karro et al., 2007),
the two most comprehensive pseudogene annotation data-
bases. Genomic coordinates of 934 unique pseudogene
transcript clusters in our data set were found to overlap with
the pseudogene coordinates annotated in both Yale and
ENCODE databases. In addition, 585 clusters overlapped with
Yale and 92 with ENCODE databases, displaying a high degree
of overall concordance between our data and the authentic
resources and highlighting a level of difference between the
two reference databases (that necessitated our consideration
of both resources). Further, as multiple clusters can sometimes
represent one distinct pseudogene transcript, the 2,156
transcript clusters provided evidence for 2,082 distinct tran-
scripts. Of these, 1,506 transcripts overlap with the genomic
coordinates of pseudogenes in Yale and/or ENCODE, and up
to 576 transcripts are potentially novel (described below)
(Figure S2A). The 2,082 pseudogene transcripts, in turn, corre-
spond to 1,437 wild-type genes, clearly indicating that the
transcripts of multiple pseudogenes arisen from the same wild-
type genes are also detected in our compendium. Taken
together, our study provides evidence of widespread transcrip-
tion of pseudogenes unraveled by high-throughput transcrip-
tome sequencing (Table S3).
Pseudogene clusters across the sample-wise compendium
reveal that pseudogenes of housekeeping genes such as
ribosomal proteins are widely expressed across tissue types.1624 Cell 149, 1622–1634, June 22, 2012 ª2012 Elsevier Inc.Additionally, pseudogene transcripts corresponding to CALM2
(calmodulin 2 phosphorylase kinase, delta), TOMM40 (translo-
case of outer mitochondrial membrane 40), NONO (non-POU
domain-containing, octamer-binding), DUSP8 (dual-specificity
phosphatase 8), PERP (TP53 apoptosis effector), and YES
(v-yes-1 Yamaguchi sarcoma viral oncogene homolog 1), etc.
were observed inmore than 50 samples each, whichwere further
validated by pseudogene-specific RT-PCR followed by Sanger
sequencing (Table S4).
Further, because our RNA-Seq compendium comprises 35- to
45-mer short sequence reads that largely generated short
sequence clusters not optimal for available pseudogene analysis
tools such as Pseudopipe (Zhang et al., 2006) and Pseudofam
(Lam et al., 2009) used in generating ENCODE and Yale data-
bases, we carried out a direct query of individual clusters against
the human genome (hg18) using the BLAT tool from UCSC,
which is ideally suited for short sequence alignment searches
(Kent, 2002). Based on this ‘‘custom’’ analysis, or simply BLAT
(Figure S2A), we were able to independently assign 1,888
clusters representing 1,820 unique pseudogenes to unique
genomic locations.
Detection of Potentially Novel Pseudogene Transcripts
Comparing the genomic locations of the pseudogene clusters
identified by BLAT analysis to those identified by Yale and
ENCODE databases (Figure S2A), 762 clusters were found to
be common to all three resources, but a remarkably large set
of 585 clusters was uniquely defined by BLAT analysis alone.
Some of the pseudogene transcripts thus identified included
BAT1, BTBD1, COX7A2L, CTNND1, EIF5, PAPOLA, PARP11,
SYT, ZBTB12, and others (n = 25) and were validated by Sanger
sequencing (Table S4). Thus, analysis of RNA-Seq data provided
a reliable assessment of expressed pseudogenes.
Though designating the BLAT-based pseudogene clusters
as novel pseudogenes must await further sequence character-
ization (such as analysis of ORF structure and potential genesis
of novel protein-coding gene family members, etc.), a small
subset of clusters was seen to be localized in the vicinity of
known pseudogenes. Thus, we found 92 clusters that resided
adjacent (within 5 kb) to previously annotated pseudogenes
(Figure S2B, left), and we hypothesize that these may represent
pseudogenes with inaccurate annotations in the current
databases. For example, the chromosomal coordinates of
CENTG2-J (OTTHUMT00000085288, Havana processed
pseudogene) are defined in ENCODE as Chr1:177822463-
177824935. As expected, we observed a cluster mapping to
this locus; however, interestingly, we also observed a distinct
cluster (Chr1:177825028-177826295) less than 100 base pairs
away. Although unannotated in the current databases, the
sequence of this adjacent locus shows a high degree of
homology to the CENTG2 parental gene (Figure S2B, right),
strongly suggesting that this cluster represents an extension of
the existing genomic coordinates of CENTG2-J annotation.
Similar observations were made with HNRNPA1 and the
HNRNPA1-J on Chr6q27 (Figure S2B, right). 493 BLAT derived
clusters that were not in close proximity to annotated pseudo-
genes likely represent putative pseudogenes currently missing
in the database annotations (Table S3B).
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Figure 2. Schematic Representation of Cluster Alignments with Pseudogene Transcripts
(A and B) The relative genomic structures of the parental genes are shown aligned to the respective pseudogenes, with their chromosomal locations indicated on
the sides, (A) ATP8A2-J and (B) CXADR-J. The sequencing alterations distinguishing the pseudogene from the parental gene are indicated in red. The
pseudogene transcripts are illustrated as black bars with red hatches, which indicate divergence from the parental sequence, and the length of the transcript in
base pairs is shown on the side. These representations are then overlaid with schematics of paired-end reads used to form pseudogene clusters (in blue),
followed by overlapping sequences in a zoomed-in region of the cluster. A comparative representation of the parental (WT) and pseudogene (J) sequences for
the specified region is shown on top.
See also Figure S4.Next, we assessed the technical and analytical factors influ-
encing the yield of pseudogene transcripts. Asmay be expected,
a positive correlation was observed between the sequencing
depth and total number of pseudogene transcripts (correlation
coefficient, +0.65) (Figure S3A). However, no significant correla-
tion was observed between the absolute measure of percent
similarity between pseudogene-WT pairs and pseudogene yield.
Importantly, the metric of overall percent similarity accounts for
gap penalty and mismatches in BLAT search, but it is the ‘‘distri-bution’’ of the mismatches that is critical in resolving pseudo-
genes from nearly identical wild-type sequences; for example,
a few mismatches, accumulated in a small stretch, are more
effective in confidently distinguishing pseudogene expression
from wild-types as compared to a higher number of mismatches
that are scattered over long stretches of sequence (Figure 2).
Thus, three primary factors determine the detection of pseudo-
gene transcription by RNA-Seq: (1) the level of expression of
the pseudogenes (i.e., the higher the level of expression, theCell 149, 1622–1634, June 22, 2012 ª2012 Elsevier Inc. 1625
higher the likelihood of detection), (2) the depth of RNA
sequencing, and (3) overall distribution of mismatches with
respect to the wild-type.
To explore the loci of transcription regulatory elements associ-
ated with pseudogene transcription, we carried out ChIP-Seq
analysis of a breast cancer cell line MCF7 probed with
H3K4me3, a histone mark associated with transcriptionally
active chromosomal loci, and integrated the results with the
MCF7 pseudogene transcript data. Interestingly, we observed
a statistically significant enrichment of H3K4me3 peaks at
expressed pseudogene loci as compared to nonexpressed
pseudogenes (p = 0.0054) (Figure S3B), suggesting that the
pseudogene transcripts observed by RNA-Seq are associated
with transcriptionally active genomic loci. Interestingly, the pseu-
dogene transcripts associated with H3K4me3 peaks encom-
pass both unprocessed and processed pseudogenes, with no
discernible differences in the pattern of expression. Considering
the role of 30 UTRs with MREs in ceRNA regulatory networks, we
also looked at the frequency of 30 UTR sequences retained in our
set of pseudogene transcripts and observed that at least 71% of
all pseudogene transcripts retain distinct 30 UTR sequences
similar to their cognate wild-type genes (Figure S3C). Interest-
ingly, comparing the pseudogene transcripts with a list of genes
implicated in ceRNA networks (Han et al., 2011b; Tay et al.,
2011), we observed more than 400 overlapping transcripts
(Table S5). The presence of noncoding pseudogene transcripts
with similar 30 UTRs (and MREs) adds a further level of
complexity to ceRNA regulatory networks.
Next, we assessed a potential correlation between the expres-
sion of pseudogenes present within the introns of unrelated,
expressed genes with their ‘‘host’’ genes. Interestingly, no signif-
icant association was observed, suggesting that pseudogenes
are likely subject to independent regulatory mechanisms even
when residing within other transcriptionally active genes.
Further, our observations with the breast-specific unprocessed
pseudogene ATP8A2 (likely arisen from duplication of wild-
type ATP8A2, thus likely harboring similar promoter elements)
also indicate that there is no apparent correlation between
the pseudogene expression with the wild-type gene that is
expressed ubiquitously (described later). Thus, in summary,
although it is tempting to speculate that pseudogene expression
may be regulated by the promoter elements from the cognate
gene or the host genes, our data suggest that more complex/
indirect factors may be at play. Next, we assessed a possible
correlation between the expression of pseudogenes with that
of cognate wild-type genes, and intriguingly, no significant
pattern of correlation was observed (Figure S3D).
Focusing on the pseudogenes whose genomic coordinates
are annotated in the reference databases, we next analyzed
the expression profiles of the 1,056 unique transcripts.
Patterns of Pseudogene Expression in Human Tissues
Analyzing the expression data from 248 cancer and 45 benign
samples from 13 different tissue types (total 293 samples), we
observed broad patterns of pseudogene expression, including
1,056 pseudogenes that were detected in multiple samples
(Table S6), which supports the hypothesis that transcribed pseu-
dogenes contribute to the typical transcriptional repertoire of1626 Cell 149, 1622–1634, June 22, 2012 ª2012 Elsevier Inc.cells. In addition, we identified distinct patterns of pseudogene
expression, akin to that of protein-coding genes, including 154
highly tissue/lineage-specific and 848 moderately tissue/
lineage-specific (or enriched) pseudogenes (Figure 3A). More-
over, we found 165 pseudogenes exhibiting expression in
more than 10 of the 13 tissue types examined, and these we
classified as ubiquitous pseudogenes whose transcription is
characteristic of most cell types (Figure 3A, bottom).
Of the 165 ubiquitous pseudogenes, a majority belonged to
housekeeping genes, such as glyceraldehyde 3-phosphate
dehydrogenase (GAPDH), ribosomal proteins, several cytokera-
tins, and other genes widely expressed in most cell types. This is
expected, as these genes are known to have numerous pseudo-
genes, and it is likely that several of these pseudogenes retain
the capacity for widespread transcription, mimicking their
protein-coding counterparts.
A second set of pseudogenes exhibited near ubiquitous
expression but were frequently transcribed at lower levels in
most tissues and robustly transcribed in one or two tissues.
These pseudogenes were termed ‘‘nonspecific,’’ and this group
harbors more than 870 pseudogenes, comprising a large portion
of our data set (Figure 3A, middle). Many of the pseudogenes
previously shown to be expressed were found in this category,
including some pseudogenes reported as tissue specific,
such as CYP4Z2P, a pseudogene previously reported to be ex-
pressed only in breast cancer tissues (Rieger et al., 2004). Other
candidates observed in this category include pseudogenes
derived from Oct-4 (Kastler et al., 2010), Connexin-43 (Bier
et al., 2009; Kandouz et al., 2004), and BRAF (Zou et al., 2009),
among others (Table S6).
Though powerful, our approach is nevertheless limited to
pseudogene transcripts that are expressed above the current
threshold of detection by RNA-Seq and possess distinct
stretches of sequence mismatches compared with their
protein-coding parental genes. Thus, for example, PTENP1,
a pseudogene of PTEN recently implicated in the biology of the
phosphatidylinositol 3-kinase (PI3K) signaling pathway, was
not detected in our compendium possibly due to the preponder-
ance of cancer samples in our cohort, which tend to show low
expression or deletion of this pseudogene (Poliseno et al., 2010).
Lineage- and Cancer-Specific Pseudogene Expression
Signatures
Lineage-specific pseudogene transcripts may have the potential
for lineage-specific functions and may represent novel elements
that facilitate biological characteristics that are unique to distinct
tissue types. In this regard, we observed 154 pseudogenes with
highly specific expression patterns, including pseudogenes
derived from AURKA (kidney samples), RHOB (colon samples),
and HMGB1 (myeloproliferative neoplasms [MPNs]) (Figure 3A,
top). Interestingly, however, lineage-specific pseudogenes
tended to represent a small fraction of all pseudogenes ex-
pressed in a given tissue type, and the total number of lineage-
specific pseudogenes observed in a tissue type did not show
a correlation with the total number of samples analyzed. For
example, B-lymphocyte cells (n = 19) and MPNs (n = 9) showed
more lineage-specific pseudogenes than breast (n = 64) or pros-
tate (n = 89). Conversely, we did observe more pseudogene
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Figure 3. Tissue/Lineage-Specific Pseudogene Expression Profiles
(A) Heatmap of pseudogene expression sorted on the basis of tissue-
specific expression displays tissue-specific (top), tissue-enriched/nonspecific
(middle), and ubiquitously expressed pseudogenes (bottom).
(B) Zoomed-in version of the top panel displaying tissue-specific expressed
pseudogenes. The columns represent different tissues, with the number of
samples in parentheses. The rows represent individual clusters mapping to
specific pseudogenes. The color intensity represents the frequency (%) of
samples in a tissue type showing expression of a given pseudogenes
(according to the scale indicated at the bottom). The key clusters are labeled
with their corresponding parental gene symbols. MPN, myeloproliferative
neoplasms.
See also Table S6.transcripts in samples with longer read lengths and deeper
coverage, as expected. Together, these data both confirm and
formalize previous anecdotal observations of lineage-specific
pseudogene expression patterns by exploiting the power of
RNA-Seq to resolve individual transcripts (Figure 3B) (Bier
et al., 2009; Lu et al., 2006; Rieger et al., 2004; Zou et al., 2009).
Because our sample compendium has a substantial number of
cancer samples, we next focused on pseudogenes with cancer-
specific expression. Though a majority of the pseudogenes
examined were found in both cancer and benign samples, we
observed 218 pseudogenes expressed only in cancer samples,
of which 178 were observed in multiple cancers and 40 were
found to have highly specific expression in a single cancer
type only (Figure 4A and Table S7). Consistent with our previous
results (Figure 3), we found that the number of cancer-type-
specific pseudogenes did not correlate with the number of
samples sequenced in a given cancer type. These results
suggest that cancer samples harbor transcriptional patterns of
pseudogenes that are both lineage and cancer specific.
Among the cancer-specific pseudogenes, a few noteworthy
examples included pseudogenes derived from the eukaryotic
translation initiation factors EIF4A1 and EIF4H, the heteroge-
neous nuclear ribonucleoproteinHNRPH2, and the small nuclear
ribonucleoprotein SNRPG (Figure 4B). Moreover, we observed
pseudogenes corresponding to known cancer-associated
genes, including RAB-1, a Ras-related protein; VDAC1,
a type-1 voltage-dependent anion-selective channel/porin;
RCC2, a regulator of chromosome condensation 2; and PTMA,
prothymosin alpha. Interestingly, the parental protein-coding
PTMA gene has given rise to five processed pseudogenes that
retain consensus TATA elements, individual transcriptional start
sites, and intact open reading frames that may potentially code
for proteins closely related to the parental PTMA protein. Impor-
tantly, we find expression of PTMA-derived pseudogenes in
more than 30 cancer samples, but not in any benign cells, and
these data suggest that PTMA-derived pseudogenes may not
only contribute transcripts to cancer cell biology but potentially
proteins as well, warranting further study of these pseudogenes
in tumorigenesis.
Prostate Cancer Pseudogenes
To investigate individual pseudogenes in greater detail, we
focused on pseudogenes associated with prostate and breast
cancer, as our compendium has a substantial number of these
two cancer types represented. Analysis of lineage-specific pseu-
dogenes restricted to prostate cancers identified numerous
pseudogenes, including several derived from parental genes
known to be altered or dysregulated in cancer; for example,
NDUFA9, which encodes an NADH oxidoreductase component
of mitochondrial complex I that is reported to be upregulated in
testicular germ cell tumors (Dormeyer et al., 2008); EPCAM, an
epithelial cell adhesion molecule involved in cancer and stem
cells signaling (Munz et al., 2009); and CES7, known to be ex-
pressed only in the male reproductive tract (Gang et al., 2011)
(Figure 3B and Table S6). Among the prostate cancer specific
pseudogenes,CXADR-J, a processed pseudogene on chromo-
some 15, was of immediate interest, as the parental CXADR
protein demonstrates putative tumor suppressor functions andCell 149, 1622–1634, June 22, 2012 ª2012 Elsevier Inc. 1627
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Figure 4. Cancer-Specific Pseudogene Expression Profiles
(A) Heatmap of pseudogene expression sorted according to cancer-specific
expression patterns displays pseudogene transcripts specific to individual
cancers (top), common across multiple cancers (tissue-enriched; middle), and
nonspecific (bottom).
(B) Zoomed-in version of the top panel displaying individual cancer-specific
expressed pseudogenes. The columns represent different tissues with the
number of samples in parentheses. The rows represent individual clusters
mapping to specific pseudogenes. The color intensity represents the
frequency (%) of samples in a tissue type showing expression of a given
pseudogenes (according to the scale indicated at the bottom). The key clus-
ters are labeled with their corresponding parental gene symbols.
See also Figure S6 and Table S7.
1628 Cell 149, 1622–1634, June 22, 2012 ª2012 Elsevier Inc.its loss is implicated in a-catenin silencing (Pong et al., 2003). We
therefore selected this pseudogene for further study in prostate
cancer and first evaluated custom Taqman assays that could
distinguish CXADR-J from parental CXADR. The expression
levels showed strong correlation with the RNA-Seq data (Fig-
ure S3E). CXADR-J expression was found to be upregulated
in 25% of prostate cancer tissues, with minimal expression
seen in benign prostate samples and nonprostate tissues (Fig-
ure 5A). No correlation was observed between CXADR-J and
parental CXADR expression, although parental CXADR also
had some proclivity for prostate cancer-specific expression (Fig-
ure 5B). Interestingly, CXADR-J expression was nearly
restricted to prostate cancers lacking an ETS gene fusion, with
few ETS-positive samples exhibiting expression of this pseudo-
gene. By contrast, parental CXADR gene expression was found
in both ETS-positive and ETS-negative samples (Figure 5C).
Finally, we interrogated CXADR-J and CXADR parental gene
expression in a set of six prostate patients with matched cancer
and benign tissues (including four ETS-negative and two ETS-
positive pairs). Again, ETS-negative prostate cancer samples
displayed marked upregulation of CXADR-J compared to the
ETS-positive patients, with parental CXADR expression being
fairly constant between this set of patients (Figure 5D). To estab-
lish the expression of CXADR-J transcript, we were able to
clone CXADR-J cDNA from two RNA-Seq-positive prostate
cancer samples (Figure S5A), and as predicted, these clones
showed perfect sequence similarity to the pseudogene
CXADR-J and only 84% toCXADRwild-type gene (Figure S5B).
In the course of these analyses, we also identified a prostate-
cancer-specific readthrough transcript involving KLK4, an
androgen-induced gene, and KLKP1, an adjacent pseudogene.
This chimeric RNA transcript KLK4-KLKP1, combining the first
two exons of KLK4 with the last two exons of KLKP1, retains
an open reading frame incorporating 54 amino acids encoded
by the KLKP1 pseudogene in the putative chimeric protein (Fig-
ure S6A). Curiously, this readthrough was recently described in
the prostate cancer cell line LNCaP as a cis sense-antisense
chimeric transcript (Lai et al., 2010). Intriguingly, the KLK4-
KLKP1 transcript was highly expressed in 30%–50% of prostate
cancer tissues, and this expression was lineage and cancer
specific, with minimal expression seen in benign prostate and
other tissues (Figure S6B). These data suggest that the KLK4-
KLKP1 may warrant further study as a potential biomarker of
prostate cancer as well as a candidate protein implicated in
the biological complexity of this disease.
Breast Cancer Pseudogenes
Among the pseudogene candidates in breast cancer, we identi-
fied a unprocessed pseudogene cognate to ATP8A2, a LIM
domain-containing protein speculated to be associated with
stress response and proliferative activity (Khoo et al., 1997)
(Figure 3A, top, and Table S3). Because ATP8A2-J on chromo-
some 10 displays substantial sequence divergence from the
cognate ATP8A2-WT gene on chromosome 13, it lends high
confidence to our computational identification, and we selected
this candidate for further validation. Taqman assays distinguish-
ing ATP8A2-WT transcripts from ATP8A2-J showed a strong
correlation (r2 = 0.98) with the expression pattern obtained
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Figure 5. Expression of CXADR-J in Prostate Cancer
(A and B) Histogram of expression values (y axis) ofCXADR-J (A) andCXADR-WT (B) across a panel of tissue samples (x axis). The order of samples on the x axis
is identical in both graphs to facilitate a visual comparison.
(C) A summary histogram of the expression values of CXADR-J and CXADR-WT in prostate cancers either harboring or lacking an ETS transcription factor gene
fusion or in nonprostate samples.
(D) Expression of CXADR-J and CXADR-WT in matched pairs of tumor and benign samples from prostate cancer patients. The patients’ ETS status is indicated
by the bar below.
T, prostate cancer; B, matched benign adjacent prostate. The expression values were normalized againstGAPDH. Error bars represent means ± SE of the mean.
See also Figure S5.
Cell 149, 1622–1634, June 22, 2012 ª2012 Elsevier Inc. 1629
0500
1000
1500
2000
2500
3000
3500
4000
ATP8A2-Y
Cancer 
Cell Lines
Benign
Cell Lines
Cancer 
Tissues
Benign
Tissues
CML
Lung
Melanoma Pancreas Prostate
0
50
100
150
200
250
300
350
400
ATP8A2-WT
RQ
- A
TP
8A
2-
Y
/
G
A
PD
H
RQ
- A
TP
8A
2-
W
T/
 G
A
PD
H
0
500
1000
1500
2000
2500
3000
3500
4000
Br
Ca
ATP8A2-Y ATP8A2-WT
RQ
- A
TP
8A
2/
 G
A
PD
H
A
B
0
200
400
600
800
1000
1200
1400
1600
RQ
- A
TP
8A
2/
 G
A
PD
H
7000
90000
1000
2500
Cancer 
Cell Lines
Benign
Cell Lines
Cancer 
Tissues
Benign
Tissues
CML
Lung
Melanoma Pancreas Prostate
(n
=7
4)
Br
N
(n
=1
8)
Ot
he
r
(n
=4
6) Lu
m
(n
=1
5) Ba
(n
=1
1)
0
2000
4000
6000
8000
10000
12000
14000
16000
18000
1 4 7
Cama-1
Days
Ce
ll 
N
um
be
r
0
5000
10000
15000
20000
25000
30000
1 3 5
HCC1806
Days
Ce
ll 
N
um
be
r
0
500
1000
1500
2000
2500
3000
3500
4000
1 3 5
H16N2
Days
Ce
ll 
N
um
be
r
C
0
1000
2000
3000
4000
5000
6000
Day1 Day2 Day3
vector
ATP8A2-Y
TERT-HMEC
0
10
20
30
40
50
60
70
80
1 3 5 7 9 11 13 15 17 19 21 23 25 27
0
0.2
0.4
0.6
0.8
1
1.2
A
b
so
rb
an
ce
 (m
ig
ra
ti
o
n
)
Ce
ll 
N
um
be
r
0
0.2
0.4
0.6
0.8
1
1.2
A
b
so
rb
an
ce
 (i
nv
as
io
n
)
D
E
vector
ATP8A2-Y
TERT-HMEC
hours
NT
C
W
T1Y1 NT
C
W
T1Y1
NTC
WT 1
WT 2
Y1
Y2
NTC
WT 1
WT 2
Y1
Y2
NTC
WT 1
WT 2
Y1
Y2
F
50
100
150
200
250
300
350
20
40
60
80
100
120
140
160
180
# 
In
tr
av
as
et
ed
 c
el
ls
 in
 t
h
e 
lo
w
er
 C
A
M
# 
M
et
as
ta
ti
c 
ce
lls
 in
 c
h
ic
ke
n
 lu
n
g
NT
C
W
T1 Y1 NT
C
W
T1 Y1
Figure 6. Expression of ATP8A2-J in Breast Cancer
(A and B) Histogram of expression values (y axis) of ATP8A2-J (A) and ATP8A2-WT (B) across a panel of tissue samples (x axis). The order of samples on the x
axis is identical in both graphs to facilitate a visual comparison. (Inset) A summary histogram of the expression values of ATP8A2-J and ATP8A2-WT in breast
cancer samples relative to benign breast and other tissues (left) and luminal versus basal breast cancer subtypes (right). The expression values were normalized
against GAPDH.
(C) Cell proliferation assays following siRNA knockdowns of ATP8A2-WT and -J as indicated. NTC, nontargeting control; WT, siRNA against wild-type
ATP8A2; J, siRNA against ATP8A2-J.
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by RNA-Seq (Figure S3E), with ATP8A2-J expression found to
be restricted to breast samples, the highest levels seen in
a subset of breast cancer tissues and cell lines (Figures 6A and
6B). By contrast, ATP8A2-WT expression was highly variable
across different tissue types and showed no correlation with
ATP8A2-J expression (Figure 6B).
We were further intrigued by the pattern of ATP8A2-J expres-
sion within breast tumors, where 25% of tumors demonstrate
extremely high levels of this pseudogene, suggesting that
ATP8A2-J may contribute to a particular subtype of breast
cancer. We therefore analyzed ATP8A2-J expression with
respect to luminal and basal breast subtypes, two prominent
categories of breast cancer with distinct molecular and clinical
characteristics. Unexpectedly, we found that ATP8A2-J
expression was restricted to tumors with luminal histology,
whereas basal tumors showed minimal expression of this pseu-
dogene (Figure 6A, right). The wild-type ATP8A2 transcript did
not display this pattern of expression.
To investigate a potential role of ATP8A2-J expression in
breast cancer, first we carried out siRNA-based knockdown of
both the wild-type and pseudogene RNA in two independent
breast cancer cell lines that expressed both the transcripts (Fig-
ure S7A). Knockdown of ATP8A2-J with two independent
siRNAs was found to specifically inhibit the proliferation of over-
expressing cell lines Cama-1 and HCC1806 (Figure 6C), but not
the cell lineswith nodetectable levels ofATP8A2-J, for example,
the benign breast epithelial cell line H16N2 (Figure 6C, right) and
a pancreatic cancer cell line, BXPC3 (Figure S7D). Knockdown of
ATP8A2-J (but not ATP8A2-WT) also resulted in reduced cell
migration and invasion seen in in vitro Boyden Chamber assays
(Figure 6D) as well as in in vivo intravasation and metastasis in
chicken chorioallantoic membrane xenograft assay (Figure 6F).
In contrast, knockdown of wild-type ATP8A2 had no effect on
the proliferation of any of the cell lines tested, suggesting an
unexpected growth regulatory role for ATP8A2-J (Figure 6C).
Surprisingly, though the knockdown of wild-type ATP8A2 had
a minimal effect on the pseudogene transcript levels, ATP8A2-
J-specific siRNAs, apart from reducing the ATP8A2-J tran-
script, also reduced the wild-type protein levels (Figures S7C
and S7E). Thus clearly, unlike Oct4 and BRAF pseudogene tran-
scripts having an inverse correlation with the wild-type transcript
levels, ATP8A2-J and wild-type ATP8A2 transcripts (Figures 6A
and 6B) and protein (Figure S7E) do not seem to be regulated in
this manner. Subsequently, to assess the phenotypic effect of
ATP8A2-J overexpression in benign cells, we cloned and over-
expressed the full-length ATP8A2 pseudogene cDNA in benign
breast epithelial cell line TERT-HMEC. Two independent pooled
populations of ATP8A2-J-overexpressing TERT-HMEC cells
were found to undergo increased proliferation and migration
(Figure 6E), indicating the potential oncogenic nature of this
breast-specific pseudogene transcript.(D) Boyden chamber assay showing cell migration (left) and invasion through ma
(E and F) (E) The effect of ATP8A2-J overexpression in TERT-HMEC cells on cell p
(right) and (F) chicken chorioallantoic membrane assay of HCC-1806 cells treate
relative number of cells intravasated in the lower CAM (left) and metastatic cells
Error bars represent means ± SE of the mean.DISCUSSION
The recent advances in high-throughput transcriptome se-
quencing have revealed widespread expression of noncoding
RNAs in the context of development and differentiation (Kha-
chane and Harrison, 2010; Nagalakshmi et al., 2008; Pickrell
et al., 2010; Prensner et al., 2011; Wilhelm et al., 2008). These
studies, however, do not include pseudogene expression anal-
yses in their purview, likely due to the challenge of extremely
close sequence similarity with wild-type cognate genes. Here,
we interrogated the potential of RNA-Seq data to unambiguously
detect pseudogene transcripts and to assess whether pseudo-
gene expression is more common in the transcriptome than
previously realized. Surprisingly, we found evidence of a wide-
spread expression of pseudogenes in our cancer transcriptome
resource, including 1,500 pseudogenes annotated in the Yale
and ENCODE databases, redefined the genomic coordinates
of 100 pseudogenes in existing databases, and nominated
more than 400 potentially novel pseudogenes. In aggregate,
our analysis considerably expands the spectrum of expressed
pseudogenes documented previously (Harrison et al., 2005;
Yao et al., 2006; Zheng et al., 2007).
The extreme sequence similarity between pseudogenes and
cognate wild-type genes suggests a functional role for pseudo-
gene transcripts; indeed, pseudogene expression has been
associated with both downregulation of cognate wild-type
gene, such as eNOS in ovary, as well as a positive effect on
the expression of the wild-type gene, as demonstrated recently,
wherein PTENP1 expression upregulates PTEN expression in
prostate cells (Poliseno et al., 2010). Interestingly, a class of
pseudogenes called ‘‘unitary pseudogenes’’ does not have
extant cognate wild-type genes (Zhang et al., 2010). Neverthe-
less, as most pseudogenes do have distinct cognate wild-type
genes, we assessed the correlation between expressed pseudo-
genes and their cognate wild-type genes across multiple
samples (of the same tissue type or across diverse tissue types)
and did not observe a statistically significant correlation. This is
not surprising, partly because our data set is comprised of
a heterogeneous set of samples representing diverse tissue
types. Further, the sensitivity of detection of individual pseudo-
gene transcripts is limited by the degree and distribution of
dissimilarity with the wild-type gene that determines the ‘‘effec-
tive’’ depth of coverage; this limits the number of samples
showing measurable expression of individual pseudogene-
wild-type pairs, making it difficult to conduct robust statistical
analyses. Future studies involving larger sample sets with higher
depth of coverage and longer read length may be better able
to resolve this question.
Taken together, our study provides a systematic approach to
analyze expressed pseudogenes using RNA-Seq data, enabling
comparisons of cancer versus benign tissues in multiple solidtrigel (right).
roliferation (left) and cell migration based on Incucyte wound confluency assay
d with nontargeting control siRNA, ATP8A2-WT, or ATPA2-J siRNA showing
in chicken lung (right).
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tumors. Our efforts lend additional credence to the capacity of
RNA-Seq to ‘‘re-define’’ the functional elements of the genome
and ‘‘re-annotate’’ the population of pseudogenes implicated
in human cell biology. Our approach overcomes the limitations
of previous analyses of pseudogene expression, which were
primarily anecdotal and heterogeneous in nature, and our meth-
odologies suggest avenues to reconcile the difficulty in distin-
guishing pseudogene expression from parental protein-coding
gene expression—a facet that is important for all RNA-Seq
studies aiming to provide an accurate picture of gene expres-
sion. Finally, we describe ATP8A2-J and CXADR-J pseudo-
genes preferentially associated with distinct subsets of breast
cancer and prostate cancer patients, respectively.
The recent description of intricate regulatory networks of
protein-coding transcripts called competitive endogenous
RNAs (ceRNAs) defined on the basis of coordinated regulation
by common sets of microRNA response elements (MREs)—first
intimated by Salmena et al. (Salmena et al., 2011) and sub-
sequently supported by experimental results from multiple
groups(Cesana et al., 2011; Han et al., 2011b; Karreth et al.,
2011; Tay et al., 2011)—implicates potential noncoding func-
tions for many protein-coding transcripts. In this context,
pseudogene transcripts could provide an additional layer of
complexity in conjunction with their cognate wild-type genes
or independently.
The cancer/tissue-specific pseudogene expression signa-
tures described here highlight the need to factor in pseudogene
expression in all high-throughput gene expression studies and
also show that pseudogene expression merits further explora-
tion in its own right as an additional layer of transcriptional
complexity. To facilitate further analyses, we provide here an
extensive resource of RNA-Seq data of human cancer-related
tissues and cell lines.EXPERIMENTAL PROCEDURES
Data Set
Paired-end transcriptome sequence reads (2 3 40 and 2 3 80 base pairs)
were obtained from a total of more than 293 samples from 13 tissue types (Fig-
ure S1 and Table S1). Each sample was sequenced on an Illumina Genome
Analyzer I or II according to protocols provided by Illumina as described earlier
(Palanisamy et al., 2010).
Pseudogene Analysis Pipeline
Paired-end transcriptome reads were mapped to the human genome
(NCBI36/hg18) and University of California Santa Cruz (UCSC) Genes using
Efficient Alignment of Nucleotide Databases (ELAND) software of the Illumina
Genome Analyzer Pipeline, using 32 bp seed length and allowing up to two
mismatches; detailed mapping status is represented in Table S2. Passed
purity filter reads obtained from Illumina export and extended output files (as
described before) were parsed and binned into three major categories: (1)
both of the paired reads map to annotated genes; (2) one or both of the paired
reads map to unannotated regions in the genome; and (3) neither of the reads
map (these include viral, bacterial, and other contaminant reads, as well as
sequencing errors). The paired reads with one or both partners mapping to
an unannotated region were clustered based on overlaps of aligned
sequences using the chromosomal coordinates of the clusters. Singleton
reads that did not cluster or stacked\duplicated reads with the same start
and stop genomic coordinates (potential PCR artifacts) were filtered out.
Passed filter clusters were defined as units of transcript expression (analogous
to a ‘‘probe’’ on microarray platforms). These clusters were screened against1632 Cell 149, 1622–1634, June 22, 2012 ª2012 Elsevier Inc.two human pseudogene resources, Yale human pseudogene (Build 53, http://
pseudogene.org/) (Karro et al., 2007) and Gencode (October 2009, http://
genome.ucsc.edu/ENCODE/) (Zheng et al., 2007), to identify and annotate
pseudogene clusters. The processed, duplicated, and fragmented categories
of pseudogene entries from Yale and the entries corresponding to Level 1+2
(Manual Gene Annotations) and Level 3 (Automated Gene Annotations) from
Gencode were used. The clusters were also subjected to homology search
using the alignment tool BLAT (http://www.soe.ucsc.edu/kent) (Kent, 2002)
for an independent annotation. Sequence reads from individual samples
were queried against the resultant clusters defined by the union of Yale,
ENCODE, andBLAT output to assess the expression of pseudogenes (Figure 1
and Table S3). The cutoff value for pseudogene expression in a sample was set
at five or more reads mapping to at least one cluster in a putative pseudogene
transcript. Pseudogene transcripts (one or more probes overlapping with
either Yale or ENCODE) detected in two or more samples in a tissue type
and absent in all other tissue types were defined as tissue/lineage specific.
Pseudogene probes detected in 10 out of 13 samples were designated as
ubiquitous. All other cases were described as an intermediate category. Pseu-
dogene transcripts detected in three or more cancer samples and absent in all
benign samples were designated as cancer specific.
We carried out multiple correlation analyses (Figure S3), including: (1)
passed filter reads (sequence yield) with total number of pseudogene tran-
scripts observed per sequencing run (pseudogene transcript coverage); (2)
expression of genes and pseudogenes carried out using 173 gene-pseudo-
gene pairs in 64 samples that each show nonzero expression in at least ten
samples across the data set; (3) expression levels of ATP8A2 and CXADR
pseudogenes obtained from RNA-Seq and qPCR; (4) ChIP-Seq analysis of
a breast cancer cell line MCF7 that was probed with H3K4me3 and compared
withMCF7 pseudogene transcript data; and (5) pseudogene transcripts with 30
UTR sequences (± 2 kb) that were compared with 30 UTR sequences of their
cognate genes using BLAT.
Pseudogene transcripts showing an overlap with transcripts involved in
ceRNA network genes reported previously were tabulated (Sumazin et al.,
2011 and Tay et al., 2011) (Table S5). The entire sequence data set will be
submitted to dbGAP after securing requisite approvals.
RNA Isolation and cDNA Synthesis
Total RNAwas isolated using Trizol and anRNeasy Kit (Invitrogen) with DNase I
digestion according to the manufacturer’s instructions. RNA integrity was
verified on an Agilent Bioanalyzer 2100 (Agilent Technologies, Palo Alto, CA).
cDNA was synthesized from total RNA using Superscript III (Invitrogen) and
random primers (Invitrogen).
Quantitative Real-Time PCR
Quantitative real-time PCR (qPCR) was performed using Taqman or SYBR
green-based assays (Applied Biosystems, Foster City, CA) on an Applied
Biosystems 7900HTReal-Time PCRSystem, according to standard protocols.
The Taqman assays for CXADR and ATP8A2 assays were custom designed
based on regions of differences between the wild-type and pseudogene
sequences (Figure S4). Oligonucleotide primers for SYBR green assays were
obtained from Integrated DNA Technologies (Coralville, IA). The housekeeping
gene GAPDH was used as a loading control. Fold changes were calculated
relative to GAPDH and normalized to the median value of the benign samples.
CXADR-J_F CGGTTTCAGTGCTCTATGTTGTTTG; CXADR-J_R TAAATT
TAGGATTACATGTTTCTAGAACA; CXADR-J_M 6FAM ATGCCATCCAA
AACCA; ATP8A2-J_F CTGGTGTTCTTTGGCATCTACTCA; ATP8A2-J_R
CAGCTCAGGATCACAGTTGCT; ATP8A2-J_M 6FAM CTGGTCCACCATT
CTC; ATP8A2-WT_F ATCCTATTGAAGGAGGACTCTTTGGA; ATP8A2-WT_R
CCAGCAAATTCCCAAGGTCAGT; ATP8A2-WT_M 6FAM AAGGGCAGCCAT
TACT; KLK4-KLKP1_F ATGGAAAACGAATTGTTCTG; and KLK4-KLKP1_R
CAGTGTTCCGGGTGATGCAG.
Additionally, inventoried Taqman assays for CXADR-WT (Hs00154661_m1)
and ATP8A2-WT (assay ID hs00185259_m1) were used.
RT-PCR and Sanger Sequencing
Sequence stretches unique to pseudogene transcripts were identified by
aligning the candidate pseudogene sequences with their corresponding
wild-type genes. PCR primers specific to pseudogene transcripts (Table S4)
were used to amplify pseudogene cDNAs from index samples followed by
Sanger sequencing of the PCR products. The resultant sequences were
analyzed using ClustalW to compare the identity between pseudogene and
cognate wild-type sequences.
Cell Proliferation Assays
Experimental cells were transfected with siRNAs using oligofectamine reagent
(Life Sciences), and 3 days posttransfection, the cells were plated for prolifer-
ation assays. At the indicated times, cell numbers were measured using
Coulter Counter.
Wound Healing Assay Using Incucyte
For the wound healing assay, vector control or ATP8A2 pseudogene-
overexpressing cells were plated at high density, and 6 hr later, uniform
scratch wounds were made using Woundmaker (Incucyte). Relative migration
potential of the cells was assessed by confluence measurements at regular
time intervals as indicated over the wound area.
ATP8A2 Pseudogene Overexpression Studies
The ATP8A2 pseudogene cDNA from breast cancer cell line HCC1806 was
cloned into pENTR-D-TOPO entry vector (Invitrogen) following manufacturer’s
instructions. Sequence-confirmed entry clones in correct orientation were
recombined into Gateway pcDNA-DEST26 mammalian expression vector
(Invitrogen) by LR Clonase II enzyme reaction following manufacturer’s
instructions. HMEC-TERT cells were transfected using Fugene 6, and poly-
clonal populations of cells expressing ATP8A2 pseudogene cDNA or empty
vector constructs were selected using geneticin. At the indicated times, cell
numbers were measured using Coulter Counter.
Chicken Chorioallantoic Membrane Assay
Chicken chorioallantoic membrane (CAM) assay for tumor growth was carried
out as follows. Fertilized eggswere incubated in a humidified incubator at 38C
for 10 days, and then CAM was dropped by drilling two holes: a small hole
through the eggshell into the air sac and a second hole near the allantoic
vein that penetrates the eggshell membrane but not the CAM. Subsequently,
a cutoff wheel (Dremel) was used to cut a 1 cm2 window encompassing the
second hole near the allantoic vein to expose the underlying CAM. When
ready, CAM was gently abraded with a sterile cotton swab to provide access
to the mesenchyme, and 23 106 cells in 50 ml volume were implanted on top.
The windows were subsequently sealed and the eggs returned to the incu-
bator. After 7 days, extraembryonic tumors were isolated and weighed. Five
to ten eggs per group were used in each experiment.
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